{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:44:11Z","timestamp":1783489451202,"version":"3.55.0"},"reference-count":8,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>To determine the optimal empiric dosing regimen to achieve therapeutic serum concentrations of vancomycin and aminoglycosides in pediatric patients who are receiving continuous renal replacement therapy (CRRT).<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This retrospective study investigated pediatric patients (&lt;18 years old) who received at least one dose of an aminoglycoside and\/or vancomycin while on CRRT and who had at least one serum concentration assessed during the study period. Rates of culture clearance and discontinuation of renal replacement therapy, pharmacokinetic variables (i.e., volume of distribution [Vd], half-life [t\u00bd], rate of elimination [ke]), and correlations between patient's age and weight in regard to the empiric dosing regimen were evaluated.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>Forty-three patients were included in this study. The median dose required to reach therapeutic serum concentrations for vancomycin was 17.6 mg\/kg (12.8\u201320.4 mg\/kg) every 12 hours (6\u201330 hours) in continuous venovenous hemodialysis (CVVHD) patients and 16.3 mg\/kg (13.9\u201321.4 mg\/kg) every 12 hours (6\u201324 hours) in continuous venovenous hemodiafiltration (CVVHDF) patients. The median dose for aminoglycosides was unable to be determined. In CVVHD patients, the median vancomycin ke was 0.04 hr<jats:sup>\u22121<\/jats:sup>, t\u00bd was 18 hours, and Vd was 1.6 L\/kg. In CVVHDF patients, the median vancomycin ke was 0.05 hr<jats:sup>\u22121<\/jats:sup>, t\u00bd was 14 hours, and Vd was 0.6 L\/kg. No correlation was found between age and weight with regard to effective dosing regimen.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>To achieve therapeutic trough concentrations in pediatric patients on CRRT, vancomycin should be dosed at approximately 17.5 mg\/kg administered every 12 hours.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-28.2.143","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:32:15Z","timestamp":1682523135000},"page":"143-148","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Dosing Regimens of Vancomycin and Aminoglycosides in Pediatric Patients on Continuous Renal Replacement Therapy"],"prefix":"10.5863","volume":"28","author":[{"given":"Mark L.","family":"Vestal","sequence":"first","affiliation":[{"name":"Department of Pharmacy (MV, TSH), Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MV, TSH), Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S.","family":"Heath","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MV, TSH), Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"11","key":"i2331-348X-28-2-143-b1","series-title":"Pediatr Nephrol","first-page":"2007","article-title":"Continuous renal replacement therapy in children","volume":"27","year":"2012","unstructured":"Sutherland\n              SM\n            ,\n\t\t\t\t\t\tAlexanderSR.\n          Continuous renal replacement therapy in children.\n\t\t\t\t\tPediatr Nephrol.\n\t\t\t\t\t2012;27(11):2007\u20132016."},{"issue":"12","key":"i2331-348X-28-2-143-b2","series-title":"N Engl J Med","first-page":"1157","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","year":"2003","unstructured":"Kearns\n              GL\n            ,\n\t\t\t\t\t\tAbdel-RahmanSM,\n\t\t\t\t\t\tAlanderSW,\n\t\t\t\t\t\n          .\n\t\t\t\t\tDevelopmental pharmacology\u2014drug disposition, action, and therapy in infants and children.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2003;349(12):1157\u20131167."},{"issue":"8","key":"i2331-348X-28-2-143-b3","series-title":"Eur J Clin Pharmacol","first-page":"1089","article-title":"Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy","volume":"75","year":"2019","unstructured":"Moffett\n              BS\n            ,\n\t\t\t\t\t\tMorrisJ,\n\t\t\t\t\t\tMunozF,\n\t\t\t\t\t\tArikanAA.\n          Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.\n\t\t\t\t\tEur J Clin Pharmacol.\n\t\t\t\t\t2019;75(8):1089\u20131097."},{"issue":"5","key":"i2331-348X-28-2-143-b4","series-title":"Pharmacotherapy","first-page":"562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","year":"2009","unstructured":"Heintz\n              BH\n            ,\n\t\t\t\t\t\tMatzkeGR,\n\t\t\t\t\t\tDagerWE.\n          Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2009;29(5):562\u2013577."},{"issue":"2","key":"i2331-348X-28-2-143-b5","series-title":"J Biomed Inform","first-page":"266","article-title":"The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement","volume":"44","year":"2011","unstructured":"Horvath\n              MM\n            ,\n\t\t\t\t\t\tWinfieldS,\n\t\t\t\t\t\tEvansS,\n\t\t\t\t\t\n          .\n\t\t\t\t\tThe DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement.\n\t\t\t\t\tJ Biomed Inform.\n\t\t\t\t\t2011;44(2):266\u2013276."},{"issue":"2","key":"i2331-348X-28-2-143-b6","series-title":"J Biomed Inform","first-page":"377","article-title":"Research Electronic Data Capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","year":"2009","unstructured":"Harris\n              PA\n            ,\n\t\t\t\t\t\tTaylorR,\n\t\t\t\t\t\tThielkeR,\n\t\t\t\t\t\n          .\n\t\t\t\t\tResearch Electronic Data Capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support.\n\t\t\t\t\tJ Biomed Inform.\n\t\t\t\t\t2009;42(2):377\u2013381."},{"issue":"4","key":"i2331-348X-28-2-143-b7","series-title":"J Pediatr Pharmacol Ther","first-page":"305","article-title":"Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support","volume":"23","year":"2018","unstructured":"Zylbersztajn\n              BL\n            ,\n\t\t\t\t\t\tIzquierdoG,\n\t\t\t\t\t\tSantanaRC,\n\t\t\t\t\t\n          .\n\t\t\t\t\tTherapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2018;23(4):305\u2013310."},{"issue":"9","key":"i2331-348X-28-2-143-b8","series-title":"Clin Ther","first-page":"1976","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature","volume":"38","year":"2016","unstructured":"Sherwin\n              J\n            ,\n\t\t\t\t\t\tHeathT,\n\t\t\t\t\t\tWattK.\n          Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2016;38(9):1976\u20131994."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p143.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/2\/143\/3213251\/i2331-348x-28-2-143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p143.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p143.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:48:01Z","timestamp":1747356481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p143.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":8,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.2.143","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}